Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies Ended

2023-508756-19-00 Mesothelioma 3 2019-10-29
Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma wi… Ended

2024-514479-16-00 Unresectable, Locally Advanced or Metastatic Renal Cell 4 2019-10-28
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in… Ended

2024-512734-15-00 Non-Hodgkin lymphoma and chronic lymphocytic leukemia 1 2019-10-23
DPDIMP#1-trial: Impact of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy Ended

2024-518448-20-00 Breast cancer 11 2019-10-17
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended

2024-514873-22-00 Unresectable locally advanced and/or metastatic soft-ti 5 2019-10-16
Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study Ended

2024-514767-26-00 colorectal liver metastases 3 2019-10-11
Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended

2023-506657-38-00 Biliary Tract Carcinoma 5 2019-10-02
Clinical trial with the drug lorlatinib in patients affected by a lymphoma that expresses the protein ALK, previously treated with ALK inhib… Ended

2025-520788-42-00 Anaplastic Large Cells Lymphoma (ALCL) ALK+ 4 2019-09-26
Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended

2023-505614-17-00 Participants with advanced or recurrent endometrial car 5 2019-09-20
FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial Ended

2024-518036-36-03 Breast cancer 6 2019-09-20
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse Ended

2024-513956-14-00 Acute myeloid leukemia 4 2019-09-16
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Re… Ended

2024-515123-11-00 Lymphoma 3 2019-09-05
Study of Pembrolizumab combined with Ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR… Ended

2023-509457-31-00 metastatic colon cancer, advanced cancer of the colon 9 2019-09-01
Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended

2023-503956-29-00 Microsatellite Instability High (MSI-H) or Mismatch Rep 5 2019-08-26
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended

2024-516201-23-00 Lung Cancer, NSCLC 4 2019-08-26
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23
A Clinical Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensiv… Ended

2024-513283-26-00 Acute Myeloid Leukemia 4 2019-08-20
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced S… Ended

2024-513574-21-00 Neoplasms 1 2019-08-09
A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer. Ended

2024-515929-28-00 Non-small Cell Lung Cancer 4 2019-08-02
NeoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake. Ended

2023-507170-41-00 Solid tumors known to overexpress GRPR and with [68Ga]- 7 2019-07-29
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with lo… Ended

2023-509053-32-00 Locoregional Hepatocellular Carcinoma (HCC) 5 2019-07-17
Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513977-31-00 Untreated squamous cell carcinoma of the head and neck 4 2019-07-17
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch… Ended

2023-507498-16-00 Diffuse Large B-Cell Lymphoma (DLBCL) 9 2019-07-02
ERibulin in Advanced Solitary fibrous tumor, an ItaliaN sarcoma Group phase II study (ERASING) Ended

2024-517795-38-00 Advanced Solitary fibrous tumor 4 2019-06-26